Navigation Links
Chimerix to Present at the Citi 2011 Global Health Care Conference
Date:2/24/2011

lant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.  The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233 in addition to new funding from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extens
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
2. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
3. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
4. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
5. Chimerix to Present at 9th Annual BIO Investor Forum
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
8. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
9. Chimerix to Present at Two Upcoming Investor Conferences
10. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
11. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... SAN DIEGO , Sept. 2, 2015  Neurocrine ... Tim Coughlin , Chief Financial Officer of Neurocrine ... Conference in New York City . ... September 9 at 11:25am ET (8:25am PT).  The presentation ... Company,s website at http://www.neurocrine.com .   ...
(Date:9/2/2015)... QC , Sept. 2, 2015 Demers Ambulances ... (EEP) Inc. as their new dealer for the states of ... and Tennessee . "This ... customers," said Benoit Lafortune , Executive Vice-President for Demers ... Mississippi and Alabama ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2
... Animal Health has launched its second product in the ... milbemycin oxime), a broad-spectrum parasiticide that kills fleas and ... infestations, the prevention of heartworm disease and the treatment ... in dogs and puppies 8 weeks and older, and ...
... 17, 2011 SFA Marketing today announced a ... exclusively to working with medical device manufacturers. SFA ... more than 20 years experience working with clients ... (Logo: http://photos.prnewswire.com/prnh/20110117/NY30375LOGO) "In response ...
Cached Medicine Technology:Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:9/2/2015)... ... 02, 2015 , ... The 2015 China Overseas Investment and ... business conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai ... will feature leading EB-5 industry professionals and Chinese private equity partners looking for ...
(Date:9/2/2015)... ... September 02, 2015 , ... World Patent Marketing, a vertically ... safety invention that protects people from crime and other hostile situations. , "The ... CEO and Creative Director of World Patent Marketing. "The industry is growing at ...
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
(Date:9/2/2015)... ... 02, 2015 , ... The payroll conference theme this year ... education covering legislative updates, including unemployment, global payroll best practices, and the latest ... Ultimate Software, the American Payroll Association, Barnett Associates, and the IRS, will keep ...
Breaking Medicine News(10 mins):Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... The Generic Pharmaceutical Association (GPhA) will discuss the results ... healthcare market intelligence company, revealing that generic pharmaceutical utilization has ... system in the last decade., What: ... ...
... Suction Provides Permanent Reduction of Excessive Sweat and Smells , ... ... sweating and body odor affects 176 million people and in most ... breakthrough procedure, Hypo Lipo , ( Axillary Curettage Suction ) ...
... 7 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... quarter ended March 31, 2009. "Our focus for the ... the NDA submission for pixantrone while we implemented final ... needed operating capital on the least dilutive terms possible ...
... 20% to $0.49 per outstanding common share from ... in Q1 2008)- Improved average monthly revenue per ... occupancy was 88.7%, down from 90.0% in Q1 ... to $497.9 million- Improved Facility Operating Income by ...
... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...
... 125,000-member Indiana American Legion today challenged the Indiana General ... plainly on behalf of the youngsters at the Indiana ... on legislators to "not use the current budget impasse ... announced by the Indiana State Department of Health, would ...
Cached Medicine News:Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 2Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 2Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 4Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 5Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 2Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 3Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 4Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 5Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 7Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 8Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 9Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 10Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 11Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 12Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 13Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 14Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 15Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 16Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 17Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 18Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 19Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 20Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 21Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 22Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 5Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 6Health News:Legion Demands 'Courage' From Legislators in Battle Over Children's Home 2
... Olympus TrueView II telescopes are based on ... unique wide field of view allows a tremendous ... view supports easy navigation in the joint with ... new quick lock mechanism for tight and secure ...
... WASCA Analyzer provides youwith new, exciting possibilities ... the WASCA Analyzeranalyzes the optical properties of ... the retina. In addition to refractive values, ... aberrations which were largely ignored in the ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
Medicine Products: